Clinical trial · Observational
Functional Lung Imaging With DECT and 4DCT
Pilot Study to Assess Lung Function Using Perfusion Blood Volume Dual Energy CT and 4DCT Derived Lung Ventilation Imaging
NCT04702607CI-TRIAL-00082211completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The basic premise of this pilot study is to enroll 40 patients over 3 years who have Stage II, III, or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation where a contrast enhanced 4DCT is planned.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| contrast enhanced 4DCT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- contrast enhanced 4DCT
- interventionNames
- Procedure: contrast enhanced 4DCT
Primary outcomes (2)
- measure
- evaluate the reproducibility of PBV DECT imaging and 4DCT derived lung ventilation for evaluating lung function
- timeFrame
- 3 years
- measure
- correlate changes of PBV DECT and 4DCT lung function images seen at ~6 months with radiation dose and with patient reported outcome quality of life
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- • To propose a novel biologic (i.e. functional) dose volume algorithm to reduce PBV and 4DCT lung function changes
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patients have histologic diagnosis of non-small cell lung cancer * Patients have AJCC stage II, III or IV disease were the plan is to receive definitive concurrent chemoradiation to 60 Gy or higher * Age \> 18 years of age * Patients are able to provide informed consent * No additional lung radiation is planned until after the 2nd CT on this study (i.e. patient does not have a solitary pulmonary nodule or second primary that the plan is to undergo SBRT) * Patient must have adequate kidney function to receive IV contrast (following institutional policy supplied by radiology). The cutoff level for serum creatinine is 1.6 mg/dL * Negative urine pregnancy test before every CT scan Exclusion criteria: * Allergy to IV iodine contrast * Severe claustrophobia * Further thoracic radiation therapy is planned.
References
Publications (0)
Data not yet available
No reference posted for this study.